Check out Dr. Jeremy Greene’s quote in the New York Times on Wednesday!

The state is taking action against three major drug companies and the big pharmacy benefit managers in an effort to temper costs for people with diabetes.

“The companies have been able to raise prices whenever they want, as a functional oligopoly with no major competitors in spite of patent expiration,” said Dr. Jeremy Greene, a professor of medicine at Johns Hopkins University. “They are locked into secret agreements with P.B.M.s — also an oligopoly with three major players — in which neither party will disclose what the true price of insulin products actually is.”

Read More: